Screener / SEC EDGAR /CIK 0001048477 /10-K filed Feb 26, 2026, compared with Feb 24, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Pharmaceuticals

Biomarin Pharmaceutical Inc BMRN

BioMarin Pharmaceutical Inc. (BioMarin, we, us or our) is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. 10-K, Item 1

Employees
3,221
Headquarters
Novato, CA
CEO
Alexander Hardy
Next results
around Jan 11, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $3.2B through the costs to a net profit of $348.9M · income statement of the 10-K

13% operating margin
Revenue to Gross profit: $2.5BRevenue to Cost of revenue: $717.4MGross profit to Operating profit: $409.5MGross profit to Operating expenses: $2.1BOperating profit to Net profit: $275.9MOperating profit to Tax: $133.6MOther income to Net profit: $73.0MOperating expenses to R&D: $921.9MOperating expenses to SG&A: $1.2B Revenue: $3.2B REVENUE $3.2B +13% Y/Y Gross profit: $2.5B · 78% margin GROSS PROFIT $2.5B 78% margin Cost of revenue: $717.4M · 22% of revenue COST OF REVENUE $717.4M 22% of revenue Operating profit: $409.5M · 13% margin OPERATING PROFIT $409.5M 13% margin · −15% Y/Y Other income: $73.0M · 2% of revenue OTHER INCOME $73.0M 2% of revenue Operating expenses: $2.1B · 65% of revenue OPERATING EXPENSES $2.1B 65% of revenue Net profit: $348.9M · 11% margin NET PROFIT $348.9M 11% margin · −18% Y/Y Tax: $133.6M · 4% of revenue TAX $133.6M 4% of revenue R&D: $921.9M · 29% of revenue R&D $921.9M 29% of revenue SG&A: $1.2B · 36% of revenue SG&A $1.2B 36% of revenue
Gross profit $2.5B 78% margin
Operating profit $409.5M 13% margin · −15% Y/Y
Net profit $348.9M 11% margin · −18% Y/Y
The full income statement, year by year

BMRN among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 12.9%, above 60% of 154 peers (their median 10.4%) REVENUE GROWTH 12.9% · above 60% Gross margin: 76.0%, above 80% of 107 peers (their median 63.4%) GROSS MARGIN 76.0% · above 80% Operating margin: 3.1%, above 35% of 138 peers (their median 10.2%) OPERATING MARGIN 3.1% · above 35% Net margin: -0.5%, above 29% of 153 peers (their median 6.8%) NET MARGIN -0.5% · above 29% FCF margin: 15.3%, above 65% of 144 peers (their median 9.9%) FCF MARGIN 15.3% · above 65% Return on capital: 2.8%, above 9% of 89 peers (their median 9.2%) RETURN ON CAPITAL 2.8% · above 9%
BMRN Peer median Below the median

What changed

48 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 26, 2026 against Feb 24, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Receivables growing faster than revenue
    Receivables +37.5% ($660.5M to $908.2M) vs revenue +12.9% ($2.9B to $3.2B), +24.6 pts apart
  • Cash from operations $828.0M vs net income $348.9M (FY ending Dec 31, 2025)
9 more checks with nothing to note
  • Inventory +5.4% ($1.2B to $1.3B) vs revenue +12.9% ($2.9B to $3.2B), -7.5 pts apart
  • Same auditor in both 10-Ks: KPMG LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Evaluation of variable consideration relating to ALDURAZYME product sales
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

48 paragraphs in Risk Factors that were not in the 10-K filed Feb 24, 2025. Quoted as filed.

All 48 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 24, 2025 10-K, ITEM 1A
    We have in the past and may in the future pursue acquisitions of other companies or businesses, which could divert our management’s attention, fail to achieve the anticipated benefits and/or expose us to other risks or difficulties. As part of our new corporate strategy, we have acquired, entered into agreements to acquire, and may…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 24, 2025 10-K, ITEM 1A
    For example, we faced significant uncertainty as to whether gene therapy would gain the acceptance of the public or the medical community. In October 2025, we announced our plan to pursue options to divest ROCTAVIAN, including exploring out-licensing opportunities. Subsequently in December 2025, we committed to a plan to voluntarily…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 24, 2025 10-K, ITEM 1A
    The pending Amicus Acquisition may not be completed on the currently contemplated timeline or terms, or at all. The consummation of the Amicus Acquisition is subject to the satisfaction or waiver of certain conditions. Satisfaction of a number of the conditions is not within our control, and it is possible that such conditions may…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 24, 2025 10-K, ITEM 1A
    In connection with the pending Amicus Acquisition, some collaboration partners, vendors or other parties with commercial relationships with either of us or Amicus may delay or defer decisions, which could adversely affect the revenues, earnings, cash flows and expenses of us or Amicus, regardless of whether the Amicus Acquisition is…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$2.1B$2.4B$2.9B$3.2B
Net income$141.6M$167.6M$426.9M$348.9M
Operating cash flow$175.9M$159.3M$572.8M$828.0M
Free cash flow$54.9M$62.6M$487.4M$725.0M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$3.2B ▲ 12.9% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

2 filings in the last 30 days · SEC EDGAR

All filings

About the company

Biomarin Pharmaceutical Inc, Novato, CA · from the 10-K filed Feb 26, 2026

BioMarin Pharmaceutical Inc. (BioMarin, we, us or our) is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Our San Rafael, California-based company, founded in 1997, has a proven track record of innovation, with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, we seek to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients.

Headquarters
Novato, CA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 2, 2026
Incorporated in
DE

Employees, at the top of the page: "As of December 31, 2025, we had 3,221 employees worldwide, of whom 1,518 were in operations, 692 were in research and development, 495 were in sales and marketing and 516 were in administration" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 26, 2026 (open at SEC), compared with the 10-K filed Feb 24, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BMRN/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.